Palabras clave
Microbiología
Mycobacterium kansasii
Micobacterias no tuberculosas
Mycobacterium tuberculosis Infectology
Microbiology
Mycobacterium kansasii
Atypical Mycobacteria
Mycobacterium tuberculosis
Cómo citar
Resumen
Esta revisión tiene como objetivo actualizar conceptos generales sobre un agente infeccioso que de cierta manera en el ámbito clínico actual ha sorprendido con su diagnóstico y manejo. Mycobacterium Kansasii es un bacilo fotocromógeno de crecimiento lento perteneciente a la familia Mycobacteriaceae. La enfermedad por Mycobacterium kansasii sigue el curso clínico similar a la infección por Mycobacterium tuberculosis y presenta síntomas en común a la tuberculosis pulmonar, Las manifestaciones clínicas más comunes asociadas a la infección por Mycobacterium kansasii son las lesiones pulmonares con cavitaciones de paredes finas con predilección por los lóbulos superiores, e incluso lesiones de otros órganos que comprenden la infección diseminada. Dentro de los métodos de diagnóstico microbiológico para este agente infeccioso podemos citar la tinción de Ziehl-Neelsen y otra variante empleada como la tinción fluorescente con auramina-rodamina. El tratamiento de la infección por Mycobacterium kansasii comprende los medicamentos usuales de la terapia antituberculosa que forman parte de la estrategia del tratamiento acortado estrictamente supervisado.
Citas
Griffith ED, aksamit T, brown-Elliott ab, catanzaro a, Daley c, et al. an official aTS/IDSa Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases. am J respir crit care Med 2007; 175: 367-416. https://doi.org/10.1164/rccm.200604-571ST
cattamanchi a, Nahid P, Marras kT, Gotway bM, Lee JT, et al. Detailed analysis of the Radiographic Presentation of Mycobacterium kansasii Lung Disease in Patients With HIv Infection. chest 2008; 133; 875-880. https://doi.org/10.1378/chest.07-2171
Smith bM, claudia PM, Schnadig Jv, boyars cM, aronson FJ, et al. Pathologic Features of Mycobacterium kansasii Infection in Patients With acquired Immunodeficiency Syndrome. arch Pathol Lab Med 2003 vol 127.
Jacobson Lk, Libshitz IH, Raad I, Rolston v Ik, Tarrand J, Whimbey E, et al. Mycobacterium kansasii infections in patients with cancer. clin infect Dis 2000; 30:965-8. https://doi.org/10.1086/313801
arend S M, Palou cerda E de, Haas P de, Janssen R, Hoeve M a, verhard E M, ottenhoff THM, Soolingen van D, Dissel van J T, et al. Pneumonia caused by Mycobacterium kansasii in a series of patients without recognised immune defect. clin Microbiol infect 2004; 10: 738-748. https://doi.org/10.1111/j.1469-0691.2004.00898.x
Tsaia c-W, Wangc J-T, Tsaib c-c, yeh k-H, et al. Disseminated Mycobacterium kansasii infection in an HIv-negative patient presenting with mimicking multiple bone metastases. Diagn Microbiol infect Dis. 2006; 54: (Issue 3), 211-216. https://doi.org/10.1016/j.diagmicrobio.2005.09.010
Field kS, cowie LR, Lung Disease Due to the More common Nontuberculous Mycobacteria. chest 2006; 129; 1653-1672. https://doi.org/10.1378/chest.129.6.1653
Garzón cM, orjuela LD, Naranjo No, Polo Lc, Grupo de Micobacterias, Instituto Nacional de Salud, Micobacterias no tuberculosas en colombia 1995 -2003. inf Quinc epidemiol nac 2005; 10(11):161-76.
León cI. Presencia de las micobacterias no tuberculosas en colombia. Médicas uis 1998; 12: 181-7.
[SEIMc] López cL Mycobacterium kansasii: heterogeneidad y su repercusión clínica y diagnóstica. Servicio de Microbiología. Hospital universitario virgen Macarena, Sevilla. Disponible en: http:// www.seimc.org/control/revisiones/micobacterias/ kansasi05.pdf Fecha de consulta: Julio 2010.
Park Hk, koh WJ, Shim TS, kwon oJ, clinical characteristics and Treatment outcomes of Mycobacterium kansasii Lung Disease in korea. yonsei Med 2010; 51; (4):552-556. https://doi.org/10.3349/ymj.2010.51.4.552
[SEIMc] Rodríguez Jc, cebrián L, Royo G, Mycobacterium kansasii: epidemiología, diagnóstico y tratamiento, servicio de microbiología, Hospital General universitario de Elche, universidad Miguel Hernández, alicante, España. Disponible en: http://www. seimc.org/control/revi_Micobac/Mkan.htm. Fecha de consulta: Julio 2010
R bellamy Susceptibility to mycobacterial infections: the importance of host genetics. Genes and immunity 2003; 4: 4-11. https://doi.org/10.1038/sj.gene.6363915
c. Howard barton, Thelma E. biggs, Stephen T. baker, Holly bowen, and Peter G. P. atkinson Nramp1: a link between intracellular iron transport and innate resistance to intracellular pathogens. J Leukoc biol 1999; 66(5):757-62. https://doi.org/10.1002/jlb.66.5.757
Neil WS and William NR The Host Immune Response to Tuberculosis. am J respir crit care Med 1998; 157: 679-691. https://doi.org/10.1164/ajrccm.157.3.9708002
khor cc, vannberg Fo, chapman SJ, Guo H, Wong SH, Walley aJ, vukcevic D, et al. cISH and Susceptibility to Infectious Diseases. n engl J Med 2010; 362: 2092-101. https://doi.org/10.1056/NEJMoa0905606
ottenhoff TH, verreck Fa, Lichtenauer-kaligis EG, Hoeve Ma, Sanal o, van Dissel JT. Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae. nat Genet 2002; 32: 97-105. https://doi.org/10.1038/ng0902-97
Scott DS and Small P. L. c. uptake and cellular actions of mycolactone, a virulence determinant for Mycobacterium ulcerans, Microbial Pathogenesis. Microb Pathog 2003; 34:91-101. References and further reading may be available for this article. To view references and further reading you must purchase this article. https://doi.org/10.1016/S0882-4010(02)00210-3
Giovanna c and Philippe c Function of Rho family proteins in actin dynamics during phagocytosis and engulfment. nature cell biology 2000; E191 -E196. https://doi.org/10.1038/35036454
Lian-yong G, Francoise Laval EH, Lawson Gk et al. Requirement for kasb in Mycobacterium mycolic acid biosynthesis, cell wall impermeability and intracellular survival: implications for therapy. Mol Microbiol 2003; 49(6):1547-63. https://doi.org/10.1046/j.1365-2958.2003.03667.x
volker b, Steven aP, Gurdyal Sb and Laurent k, MicroReview Mycobacterial lipoarabinomannan and related lipoglycans: from biogenesis to modulation of the immune response. Mol Microbiol 2004; 53(2):391-403. https://doi.org/10.1111/j.1365-2958.2004.04183.x
velasco GR, Zamorate MF, Mejía-Perea M, Micobacterias no tuberculosas: actual importancia clínica y principales factores de virulencia. Lab acta 2007; 19(3): 67-76.
Stokes WR, Norris-Jones R, brooks ED, beveridge JT, Doxsee D, and Thorson ML The Glycan-Rich outer Layer of the cell Wall of Mycobacterium tuberculosis acts as an antiphagocytic capsule Limiting the association of the bacterium with Macrophages. infect immun 2004; 72(10): 5676-5686. https://doi.org/10.1128/IAI.72.10.5676-5686.2004
Saavedra R, Segura E, Leyva R, Esparza aL, and López-Marín ML Mycobacterial Di-o-acyl-Trehalose Inhibits Mitogen- and antigen-Induced Proliferation of Murine T cells In vitro. clin Diagn Lab immunol 2001; 8(6): 1081-1088. https://doi.org/10.1128/CDLI.8.6.1-91-1088.2001
Lillo M, orengo S, cernoch P, Harris RL. Pulmonary and disseminated infection due to Mycobacterium kansasii: a decade of experience. rev infect Dis 1990; 12: 760-767. https://doi.org/10.1093/clinids/12.5.760
breathnach a, Levell N, Munro c, Natarajan S, Pedler S. cutaneous Mycobacterium kansasii infection: case report and review. clin infect Dis 1995; 20: 812-817. https://doi.org/10.1093/clinids/20.4.812
Falkinham Jo. Epidemiology of infection by non tuberculous mycobacteria. clin Microbiol rev 1996; 9: 177-215. https://doi.org/10.1128/CMR.9.2.177
attorri S, Dunbar S, clarridge JE. assessment of Morphology For Rapid Presumptive Identification of Mycobacterium Tuberculosis and Mycobacterium kansasii. J clin Microbiol. 2000; 38(4):1426-9. https://doi.org/10.1128/JCM.38.4.1426-1429.2000
crespo oM, Prado cR, alzate a, Micobacterias no tuberculosas en personas vIH positivas y en personas sin factores de riesgo a la infección. col Med 1997; 28(3): 136-134.
castro Mc, Puerto G, García ML, orjuela LD, Polo Lc, Garzón cM, Ribón W, Identificación molecular de micobacterias no tuberculosas mediante el análisis de los patrones de restricción, colombia 1995-2005, Grupo de Micobacterias, Instituto Nacional de Salud, bogotá, D. c., colombia, biomédica 2007; 27:439-46. https://doi.org/10.7705/biomedica.v27i3.206
american Thoracic Society Medical Section of the american Lung association Diagnosis and Treatment of Disease caused by Nontuberculous Mycobacteria. am J respir crit care Med 1997; 156(2): S1-S25. https://doi.org/10.1164/ajrccm.156.2.atsstatement
Park Hk, koh WJ, Shim TS, kwon oJ clinical characteristics and treatment outcomes of Mycobacterium kansasii lung disease in korea. yonsei Med J 2010; 51(4): 552-6. https://doi.org/10.3349/ymj.2010.51.4.552
Esteban J, ortiz-Pérez a current treatment of atypical mycobacteriosis expert opin Pharmacother. 2009; 10(17):2787-99. https://doi.org/10.1517/14656560903369363
Griffith DE, Management of disease due to Mycobacterium kansasii. clin chest Med 2002; 23: 613-21. https://doi.org/10.1016/S0272-5231(02)00016-3
Won-Jk, o Jung k, kyung SL, Diagnosis and Treatment of Nontuberculous Mycobacterial Pulmonary Diseases: a korean Perspective. J Korean Med sci 2005; 20: 913-25. https://doi.org/10.3346/jkms.2005.20.6.913